Table 2

Vaccine efficacy estimates against mild, moderate and severe RV gastroenteritis
Vaccine efficacya Method Source
RV1 Mild (RV episode without medical care) Moderate (GP visit) Severe (Hospitalization)b Nosocomialc
After first dose Calculated Calculated 89.8% (8.9 to 99.8) Calculated (Calculated from) Published data Efficacy for mild and moderate cases after first season calculated from efficacy ratios for mild, moderate, severe during first season [53]
First season (after second dose) 71.7% (50.4 to 83.9) 91.8% (84.0 to 96.3) 100% (81.8 to 100)
Second season 50.5% (24.3 to 67.7) 76.2% (63.0 to 85.0) 92.2% (65.6 to 99.1)
Third-fifth season Calculated Calculated Calculated Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season
RV5
After first dose Calculated Calculated 88% (65 to 97) Calculated (Calculated from) Published data Efficacy after first dose and between first and second dose for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during first season [57]
After second dose Calculated Calculated 88% (69 to 96)
First season (after third dose) 65.1% (54.1 to 73.5) 72.0% (63.2 to 78.9) 94.8% (89.4 to 97.8) (Calculated from) Published data [54,55]
Second season 49.8% (27.0 to 65.4) 58.5% (40.1 to 71.7) 90.8% (76.9 to 97.1)
Third season Calculated Calculated 100.0% (27.9 to 100) Efficacy during third season for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during second season [55]
Fourth-fifth season Calculated Calculated Calculated Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season

aVaccine efficacy was assumed equal between eligible and ineligible, data were modeled as Pert distribution; befficacy against fatal RVGE was assumed equal to efficacy for severe disease; cefficacy against nosocomial infection based on severity distribution in original study data.

GE: gastroenteritis; GP: general practitioner; RV: rotavirus.

Bruijning-Verhagen et al.

Bruijning-Verhagen et al. BMC Medicine 2013 11:112   doi:10.1186/1741-7015-11-112

Open Data